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INTRODUCTION
Reduction of glucose by the enzyme aldose reduc-
tase (AR) leads to the formation of sorbitol, which, 
in some tissues, is further oxidized to fructose upon 
sorbitol dehydrogenase-catalyzed oxidation (Suzen 
et al., 2003). Aldose reductase of the polyol metabo-
lic pathway, apart from its role as a sorbitol producer 
and detoxifier of toxic aldehydes, osmoregulator in 
the lens and kidney, and regulator of sperm matu-
ration, has been implicated in the etiology of long-
term diabetic complications (Gabbay, 1975; Gui et 
al., 1995). This enzyme is involved in many patho-
logical processes that have become major threats to 
human health. Such pathologies include a number 
of  cardiac  disorders,  inflammation,  mood  disor-
ders, renal insufficiency, and ovarian abnormalities 
(Oates, 2008; Alexiou et al., 2009). Oxidative stress 
and the polyol pathway have recently been found to 
be linked in pathological states (Suzen, 2006, 2007; 
Suzen et al., 2007). 
The important antioxidant enzyme superoxide 
dismutase (SOD) catalytically removes the superoxi-
de  radical  and  protects  organisms  from  oxidative 
damage. Superoxide is among the most abundant 
reactive  oxygen  species  (ROS)  produced  by  the 
mitochondria, and is involved in cellular signaling 
pathways. Superoxide and other ROS can damage 
cellular macromolecules and enhance the levels of 
oxidative  damage.  Superoxide  dismutase  catalyzes 
the breakdown of superoxide into hydrogen peroxi-
de and water and is therefore one of the central regu-
lators of ROS levels (Srivastava et al., 2005). Reactive 
oxygen species such as superoxide, hydrogen peroxi-
de, and hydroxyl radicals are constantly being gene-
rated intracellularly in aerobic organisms and may 
play a role in the pathogenesis of diabetes mellitus, 
ischemia-reperfusion  injury,  cancer,  inflammatory 
disease, and atherosclerosis, as well as in cell death 
and tissue injury (Thomas et al., 2000; Yildirim et 
al., 2003, 2007). Recent studies suggest that glucose 
may be an incidental substrate of AR, which appe-
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ars  to  be  more  adept  in  catalyzing  the  reduction 
of a wide range of aldehydes generated from lipid 
peroxidation. Moreover,  inhibition  of  the  enzyme 
has been shown to increase inflammation-induced 
vascular  oxidative  stress  and  prevent  myocardial 
protection associated with the late phase of ischemic 
preconditioning (Satih et al., 2005).
Basically,  the  inhibitors  of  AR  mostly  belong 
to  two  chemical  classes,  spirosuccinamide/hydan-
toins and carboxylic acids. Each class has its own 
drawbacks  regarding  selectivity,  in  vivo  potency, 
and human safety; as a result, the pathogenic role of 
AR in diabetic complications remains controversial 
(Sun et al., 2006). 
Miyomoto  (2002)  found  that  an  indole  acetic 
acid derivative showed more than 40% inhibition 
of AR at a concentration of 15 µg/mL. After a sub-
sequent optimization study based on the predicted 
docking  mode,  an  approximately  20-fold  increase 
in  inhibitory  activity  of  the  indole  derivative  was 
achieved.
The  designers  of  4-oxo-4-(4-hydroxyindole) 
butanoic acid was took into account the CoMSIA 
field and the binding mode derived by FlexX doc-
king  (Sun  et  al.,  2003).  This  rationally  designed 
compound  exhibits  an  ALR2  inhibition  with  an 
IC(50) value of 7.4 µM, which compares favorably 
to  that  of  a  well-known  ALR2  inhibitor,  tolrestat 
[IC(50) = 16 µM].
Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic  acid 
derivatives were synthesized and tested as a novel 
class of aldose reductase (ALR2) inhibitors by Da 
Settimo et al. (2003). Introduction of a halogen and 
a lipophilic group in the 5- and 1-positions, respecti-
vely, of the indole nucleus displayed the highest acti-
vity [IC(50) 0.075 µM], very close to that of tolrestat 
[IC(50) 0.046 µM]. Also, carboxymethylated hexa/
tetrahydropyridoindoles  structurally  based  on  the 
antioxidant drug stobadine were presented as novel 
ARIs capable of antioxidant activity by Stefek et al. 
(2008). A 5-(3’-indolal)-2-thiohydantoin derivative 
was found to be effective in reducing the enzyme’s 
activity compared to a corresponding well-known 
AR inhibitor (Buyukbingol et al., 1994).
A large number of structurally different com-
pounds have been studied as potent in vitro ARIs 
(Bozdağ-Dündar  et  al.,  2007,  2008;  Suzen  et  al., 
2007; Daş-Evcimen et al., 2008). However, with few 
exceptions, these compounds did not show clinical 
benefit. A compound with effective inhibition of AR 
and oxidative stress would be a most promising drug 
for the prevention of secondary diabetic complicati-
ons (Lim et al., 2001). 
Indole derivatives such as melatonin constitute 
an important class of therapeutical agents. In view of 
the ARI activity of indole derivative compounds and 
antioxidant properties of melatonin (Karbownik et 
al., 2001), we have been studying antioxidant and 
AR  inhibition  activities  of  indole  derivatives  for 
more than a decade (Ates-Alagoz et al., 2006; Suzen 
et al., 2006; Gurkok et al., 2009). Our results indicate 
that  indole  base  analogs  of  melatonin  derivatives 
have promising activities. In the light of previous 
results,  the  aim  of  this  study  was  to  investigate 
indole derivative compounds with these dual effects 
by  examining  structure-activity  relationships  with 
respect  to  inhibition  of  rat  lens  aldose  reductase 
and antioxidant action. To this end, AR and SOD 
inhibitory capacities of nine indole derivatives were 
tested in vitro.
MATERIAL AND METHODS
Chemicals
The  tested  compounds  were  all  purchased  from 
Aldrich. All solvents and reagents were of reagent 
grade and were supplied by Sigma or Aldrich.
Materials
Thirty  bovine  eyes  were  obtained  from  a  slaugh-
terhouse. They were frozen at -80ºC. Their lenses 
were taken out for isolation of the enzymes AR and 
SOD.
Isolation of aldose reductase
The enzyme AR was isolated by the method (Cerelli 
et al., 1986) described below. Pooled kidneys were 
thawed on ice and homogenized with three volu-
mes  of  distilled  water,  followed  by  centrifugation 
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was added to the supernatant to 40% saturation. The 
thick suspension was stirred for 15 min, then cen-
trifuged at 10000g for 20 min. The inert protein left 
in the supernatant was removed by increasing the 
ammonium sulfate concentration to 50% saturation, 
followed by centrifuging the mixture at 10000g for 
20 min. Aldose reductase was precipitated from the 
50% saturated solution by adding powdered ammo-
nium sulfate to 75% saturation and was recovered 
by centrifugation at 10000g for 20 min. Protein con-
centration was measured by the method of Bradford 
(1976) using bovine serum as the standard. 
Determination of aldose reductase activity
Aldose  reductase  activity  of  the  freshly  prepared 
supernatant was assayed spectrophotometrically by 
determining the decrease in NADPH concentration 
at 340 nm using a UV-1700 visible spectrophoto-
meter  (Shimatzu)  (Cerelli  et  al.,  1986)  DL-glyce-
raldehyde was used as the substrate. The enzyme 
was dissolved in 10 ml of 0.05 M NaCI solution. A 
6.40-mg quantity of protein was added to a quartz 
cuvette containing 0.1 ml of phosphate buffer (0.067 
M, pH 6.2), 0.1ml of NADPH (2 x 10-5 M final con-
centration), 0.1 ml of the test drug (10-4 M solutions 
prepared in 50% DMF-methanol), and 2.4 ml of dis-
tilled water to obtain 2.9 ml of solution. The reaction 
was started by adding 0.1 ml of DL-glyceraldehyde 
(5 x 10-5 M final concentration ) to the cuvette, and 
decrease of NADPH concentration was recorded at 
340 nm for 5 min at 37ºC. Readings were taken at 
intervals in the periods when changes in absorbance 
were linear.
Tissue sample preparation for SOD activity
Lens  tissues  were  homogenized  in  three  volumes 
of  50  mM  phosphate  buffer  (pH  7.4)  at  4oC  for 
30 sec (2 x 15 sec with a 15 sec cooling interval) 
at  2000  rpm  using  a  Teflon  glass  pestle  with  a 
Heidolph homogenizer. Cell debris was removed by 
centrifugation at 4oC and 10000g for 20 min. The 
resultant supernatant was used for measurement of 
SOD activity.
Determination of SOD activity
A simple assay system (Kostyuk et al., 1989) based 
on  the  inhibitory  effects  of  SOD  on  spontaneous 
oxidation of quercetin was used. Oxidation of quer-
cetin was previously shown to be a free radical chain 
reaction involving superoxide and hence inhibitable 
by SOD. The degree of inhibition of quercetin oxi-
dation was a function of SOD concentration. This 
reaction proved to be a very useful tool for rapid 
and highly sensitive measurement of SOD in crude 
tissue extracts and other biological samples.
The rate of quercetin oxidation in 0.016 M phos-
phate buffer (pH 9.2) was determined by observing 
absorbance changes at 406 nm spectrophotometri-
cally.  The  incubation  medium  contained  8.96  mg 
of protein, 1.405 x 10-5 M quercetin, and 0.014 M 
phosphate buffer in 3 ml. One unit is the amount of 
SOD required to inhibit the initial rate of quercetin 
oxidation by 50%.
RESULTS AND DISCUSSION
We have studied the possible effects of nine indole-
based melatonin derivatives on AR and SOD activi-
ties. All experiments were performed in triplicate. 
The results are shown in Table 1. According to the 
results,  the  highest  inhibitory  activity  on  AR  was 
observed  with  compound  8  (71%).  Compounds 
9  and  6  showed  slight  inhibitory  activity,  25  and 
21%, respectively. Other compounds did not show 
significant AR inhibitory activity (Table 1). On the 
other hand, compounds 2, 7, 8, and 9 enhanced SOD 
activity only slightly, but did not inhibit it. It was 
found that compound 6 inhibited SOD. 
Due to the limited number of available drugs for 
the treatment of diabetic complications, a number of 
reasonable approaches for the discovery of ARIs have 
been taken. It is a very well-known fact that glucose 
concentrations are often elevated in diabetics, and 
AR has long been believed to be responsible for dia-
betic complications involving a number of organs. 
Many ARIs have been developed as drug candidates, 
but virtually all have failed, although some are com-
mercially available in several countries.
Oxidative  stress,  antioxidants,  and  the  polyol 
pathway  are  known  to  be  linked  in  pathological 
states; changes in the polyol pathway can change the 
redox status of cells, thereby altering the activities of N. DAŞ-EVCIMEN ET AL. 678
Table 1. Inhibition of AR and SOD and activation of SOD by indole derivatives.
Compound  AR
 % Inhibition
SOD 
% Inhibition
SOD
 % Activity
1 14.92 ± 1.75 11.28 ± 8.20
2 5.05 ± 2.65 2.36 ± 9.83
3 1.51 ± 1.25 0.00 ± 10.02
4 0.00 ± 0.00 20.80 ± 2.15
5 8.64 ± 1.93 12.82 ± 9.86
6 21.28 ± 0.64 28.47 ± 10.27
7 14.96 ± 2.93 10.41 ± 4.63
8 71.38 ± 0.58  4.62 ± 3.56
9 25.17 ± 10.35 1.19 ± 6.28 
Fig. 1. Involvement of polyol pathway in diabetic complications. Adapted from Srivasta et al. (2005).ALDOSE REDUCTASE AND SUPEROXIDE DISMUTASE INHIBITION CAPACITIES 679
Fig. 2. Investigated indole-based analogs of melatonin derivatives.
oxidative enzymes (Thomas et al., 2000). The rela-
tionship  between  AR  activity  and  oxidative  stress 
in  tissue  sites  for  diabetic  complications  remains 
controversial. The result obtained for compound 8 
represents a promising step for further studies of AR 
inhibitory drug development. 
Owing to the pharmacophoric need of ALR-2 
(Lee et al., 1998; Schlitzer et al., 2001) for an acidic 
proton,  most  ARIs  contain  an  acetic  acid  moiety 
or  N-unsubstituted  cyclic  imides.  Introduction  of 
bioisosteric groups to the indole ring may represent 
another way to overcome unfavorable partitioning 
of acidic ARIs (Nikolaou et al., 2004; Rakowitz et 
al., 2005; Gurkok et al., 2009). Oxidative stress and 
involvement of the polyol pathway in the etiology of 
diabetic complications have been identified (Baynes 
et al., 1999; Obrosova, 2005). Based on the principle 
that a bifunctional compound with joint antioxidant/
aldose reductase inhibitory activities could be multi-
factorially beneficial, N-protected 1H-indole-5-car-
boxylic acid derivatives were proposed as potential 
ARIs (Nikolaou et al., 2002) earlier. In this study, 
compound 5 (indole-5-carboxylic acid) did not show 
noteworthy ARI or antioxidant activities.
Compound  8  (indole-3-propionic  acid,  IPA) 
has  previously  been  identified  in  the plasma  and 
cerebrospinal  fluid  of  humans.  This  compound 
completely  protected  primary  neurons  and 
neuroblastoma cells  against  oxidative  damage  and 
death caused exposure to Aß, inhibition of superoxide 
dismutase, or treatment with hydrogen peroxide. In 
kinetic competition experiments using free radical-
trapping  agents,  the  capacity  of  IPA  to  scavenge 
hydroxyl  radicals  exceeded  that  of  melatonin,  an 
indoleamine  considered  to  be  the  most  potent 
naturally  occurring  scavenger  of  free  radicals.  In 
contrast to other antioxidants, IPA was not converted 
to reactive intermediates with pro-oxidant activity. 
These  findings may  have  therapeutic  applications 
in a broad range of clinical situations (Chyan et al., 
1999).  Melatonin  and  IPA  completely  prevented 
DNA damage in hamster kidneys. Karbownik et al. Karbownik et al. 
(2001) concluded that melatonin and IPA may be concluded that melatonin and IPA may be 
effective  in  protecting  against  DNA damage and, DNA  damage  and, 
consequently, carcinogenesis. 
The results of this study suggest that compound 
8 may play an important role in antioxidant and ARI 
effects and would clearly have potential uses in the 
development of therapeutic or preventive agents for 
diabetic  complications  and  oxidative  stress-related 
diseases. 
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